Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Prostate cancer

Clinical implications of therapeutic sequence in mCRPC

Nature Reviews Urology volume 12, pages 13–14 (2015)Cite this article

Subjects

In the field of advanced prostate cancer, a number of therapeutic agents are now available. The sequence of administration of medications with distinct mechanisms of action, toxicities and efficacies, will have a critical role in disease outcomes. The identification of biomarkers predicting response will help to determine the appropriate therapeutic sequence.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Nadal, R. et al. Clinical activity of enzalutamide in docetaxel-naïve and docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. Prostate 74, 1560–1568 (2014).

    Article  CAS  Google Scholar 

  2. Schweizer, M. T. et al. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Eur. Urol. 66, 646–652 (2014).

    Article  CAS  Google Scholar 

  3. Azad, A. A. et al. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. Prostate 74, 1544–1550 (2014).

    Article  CAS  Google Scholar 

  4. Sweeney, C. et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase III randomized trial [abstract LBA2]. J. Clin. Oncol. 32 (Suppl.), 5s (2014).

    Google Scholar 

  5. Ryan, C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138–148 (2013).

    CAS  Google Scholar 

  6. Beer, T. M. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371, 424–433 (2014).

    Article  Google Scholar 

  7. Ryan, C. et al. Final overall survival (OS) analysis of COU-AA-302, a randomized phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy [abstract 7530]. Ann. Oncol. 25 (Suppl. 4), iv255–iv279 (2014).

    Article  Google Scholar 

  8. Antonarakis, E. S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371, 1028–1038 (2014).

    Article  Google Scholar 

  9. Suzman, D. L. & Antonarakis, E. S. Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther. Adv. Med. Oncol. 6, 167–179 (2014).

    Article  Google Scholar 

  10. Aparicio, A. M. et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin. Cancer Res. 19, 3621–3630 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Karmanos Cancer Institute, Wayne State University, 4100 John R. Street, 4233 HWCRC, Detroit, 48201, MI, USA

    Ulka Vaishampayan

Authors
  1. Ulka Vaishampayan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulka Vaishampayan.

Ethics declarations

Competing interests

U.V. is a speaker for Bayer, Janssen and Astellas/Medivation, a consultant for Astellas/Medivation, and has research support from Astellas/Medivation.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vaishampayan, U. Clinical implications of therapeutic sequence in mCRPC. Nat Rev Urol 12, 13–14 (2015). https://doi.org/10.1038/nrurol.2014.308

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2014.308

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing